POEWE, Werner, Pierre BURBAUD, Giovanni CASTELNOVO, Wolfgang H. JOST, Andres O. CEBALLOS-BAUMANN, Marta BANACH, Anna POTULSKA-CHROMIK, Joaquim J. FERREIRA, Katalin BIHARI, Edvard EHLER, Martin BAREŠ, Lyudmyla A. DZYAK, Anna N. BELOVA, Emmanuel PHAM, Wenzhong Jerry LIU a Philippe PICAUT. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. Movement Disorders. Hoboken: Wiley-Blackwell, 2016, roč. 31, č. 11, s. 1649-1657. ISSN 0885-3185. Dostupné z: https://dx.doi.org/10.1002/mds.26760.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial
Autoři POEWE, Werner (40 Rakousko), Pierre BURBAUD (250 Francie), Giovanni CASTELNOVO (250 Francie), Wolfgang H. JOST (276 Německo), Andres O. CEBALLOS-BAUMANN (276 Německo), Marta BANACH (616 Polsko), Anna POTULSKA-CHROMIK (616 Polsko), Joaquim J. FERREIRA (620 Portugalsko), Katalin BIHARI (348 Maďarsko), Edvard EHLER (203 Česká republika), Martin BAREŠ (203 Česká republika, garant, domácí), Lyudmyla A. DZYAK (804 Ukrajina), Anna N. BELOVA (643 Rusko), Emmanuel PHAM (250 Francie), Wenzhong Jerry LIU (840 Spojené státy) a Philippe PICAUT (643 Rusko).
Vydání Movement Disorders, Hoboken, Wiley-Blackwell, 2016, 0885-3185.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30000 3. Medical and Health Sciences
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 7.072
Kód RIV RIV/00216224:14110/16:00092396
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1002/mds.26760
UT WoS 000387415700012
Klíčová slova anglicky abobotulinumtoxinA solution for injection; cervical dystonia; Toronto Western Spasmodic Torticollis Rating Scale
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 18. 12. 2016 15:27.
Anotace
Background Approved botulinum toxin A products require reconstitution. AbobotulinumtoxinA solution for injection is a ready-to-use liquid formulation of abobotulinumtoxinA. Objectives The objective of this study was to demonstrate the superior efficacy of abobotulinumtoxinA solution for injection to placebo and to test the noninferior efficacy of abobotulinumtoxinA solution for injection versus abobotulinumtoxinA (dry formulation) in cervical dystonia. Methods This was a phase-3, multicenter, prospective, double-blind, randomized, active, and placebo-controlled study (N=369). Patients with cervical dystonia were randomized (3:3:1) to abobotulinumtoxinA solution for injection 500 U, abobotulinumtoxinA 500 U, or placebo. Following the double-blind phase, patients received abobotulinumtoxinA solution for injection, open-label, for up to 4 cycles. The primary outcome was change from baseline at week 4 of the Toronto Western Spasmodic Torticollis Rating Scale total score. Secondary measures included change from baseline or cycle baseline in Toronto Western Spasmodic Torticollis Rating Scale scores. Results At week 4, both products were superior to placebo (Toronto Western Spasmodic Torticollis Rating Scale total score least square mean decrease from baseline, abobotulinumtoxinA solution for injection 500 U -12.5, abobotulinumtoxinA 500 U -14.0, placebo -3.9; P<.0001 vs placebo). The noninferiority limit of 3 points in the Toronto Western Spasmodic Torticollis Rating Scale total score at week 4 was not met for abobotulinumtoxinA solution for injection versus abobotulinumtoxinA. Toronto Western Spasmodic Torticollis Rating Scale total score reductions were maintained for up to 4 cycles of abobotulinumtoxinA solution for injection open-label follow-up treatment. Safety profiles of abobotulinumtoxinA solution for injection and abobotulinumtoxinA were similar, with dysphagia and injection-site pain the most frequent drug-related adverse events. Conclusions Although the predefined noninferiority criterion was not met, abobotulinumtoxinA solution for injection was similarly effective to freeze-dried abobotulinumtoxinA in reducing Toronto Western Spasmodic Torticollis Rating Scale total scores with a similar safety profile. AbobotulinumtoxinA solution for injection efficacy was maintained with chronic open-label treatment, and this novel formulation may add convenience as well as dosing accuracy to treatment with abobotulinumtoxinA.
VytisknoutZobrazeno: 1. 5. 2024 15:49